LENZ Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Evert Schimmelpennink
- Full Time Employees
- 6
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 445 Marine View Avenue Solana Beach CA United States of America 92014
- IPO Date
- Mar 22, 2024
- CIK
- 0001815776
- Website
- lenz-tx.com
- Similar Companies
- Business
- LENZ Therapeutics, Inc. is a pharmaceutical company concentrating on advancing and making available treatments to enhance sight. Its flagship product, VIZZ™ (aceclidine ophthalmic solution) 1.44%, has received U.S. FDA approval for the correction of near vision in adults experiencing presbyopia. This once-daily eye drop operates as a pupil-selective miotic, creating a pinhole effect to sharpen close-up vision for up to ten hours while minimally affecting distance vision. The company has initiated the commercial launch of VIZZ™ in the United States and has established exclusive licensing and commercialization agreements for LNZ100 in territories such as Canada, Korea, and Southeast Asia. LENZ Therapeutics is based in Solana Beach, California.
LENZ Therapeutics to Participate in Upcoming Investor Conferences
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Autodesk, Celanese, DexCom, FormFactor, GitLab, Lowe’s, Matador Resources, Toast and More
LENZ Therapeutics, Inc. (LENZ) Q1 2026 Earnings Call Transcript
LENZ Therapeutics Q1 Earnings Call Highlights
LENZ Therapeutics, Inc. (LENZ) Reports Q1 Loss, Beats Revenue Estimates
LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference
LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom
LENZ Therapeutics: Speculative But Strong Buy
Why Lenz Therapeutics Stock Plummeted by Almost 20% This Week
LENZ Therapeutics (NASDAQ:LENZ) versus Abeona Therapeutics (NASDAQ:ABEO) Critical Comparison
LENZ Therapeutics, Inc. (LENZ) Q4 2025 Earnings Call Transcript
Why Lenz Therapeutics Stock Crashed Today
LENZ Therapeutics, Inc. (LENZ) Reports Q4 Loss, Misses Revenue Estimates
LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026
LENZ Therapeutics, Inc. $LENZ is Ally Bridge Group NY LLC’s 7th Largest Position
LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia
LENZ Therapeutics to Present at Upcoming Investor Conferences
Calamos Timpani Small Cap Growth Fund Q4 2025 Contributors And Detractors